We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks sadoldgit. your views always appreciated by all genuine shareholders. Please don't let the bostards get you down.
Good evening 007,
Very little movement I perceive, prolific share dumping by RF will dry up soon.
No fears of getting to end of phase 1 a and data
Rise on data results and more on progress to phase 2,
On licence early phase 2 l would hazard a good guess.
Sp been hammered before RF came aboard and decimated afterwards.
9 million market cap on a company which its lead compound is now in clinical trial dnd yet 3 years ago circa 300 million.
Market sentiment!
I have an application for shares but l reckon will get nowhere near what l applied for.
To the relief of some will not be posting for bit but will let you know if my application amount gets met. Tis only 300k worth of shares
.
Regards
There's no 1b.
the original RFO funding was for 1a and 1b because if there's no 1b there's no serious data. and if there is no serious data of trialling the drug on actual, sick people there is less chance of getting JV or license deal. but granted its only how i see it.
so now we have no 1b. and no sp. and warrants. not great. and I feel bad for anyone who is seriously down - don't believe the mad, in-humane rampers - guess what I'm not down because I never believed them.
Anyway things may well turn out OK. There's years of research in this company. 737 shows they can break through. So lets see what happens next.
Clear road ahead now Huge Value Play @ £7m Mk Cap, any news will send this flying North, Preliminary Mad results, US 1801 Patent, SRA737 News even an appearance from the shadows, Full SDC-1801 P1a data...
I will 2nd a previous post and mark this as a strong buy....
Sorry, SOG - I was researching and typing up another thread while you posted this one. Didn't mean for them to overlap.
Hi sadoldgit. Hope you are ok mate. I did not manage to get in today to buy more of these but I don't think the price will jump or go down much, till further news. Do you or potnak or other non biased readers see this any different bro me.....thanks
'They found that the probability of success was 63% in Phase I trials, 31% in Phase II trials, 58% in Phase III trials and 85% during the regulatory review process, for an overall success rate of 9.6% (63% × 31% × 58% × 85% = 9.6%).30 Jun 2016.'
Interesting Sareum are going for a phase2 and not 1b.
Involves more patients and hence more indicative of effectiveness in the indication in clinical study.
Much more meat on the bones with their intent to follow this route.
From 12 patients original intent with phase2 typically involving a couple of hundred.
My opinion here has not changed one iota in that we will better Deucravacitinib in Psoriasis.
Tom and Co clearly are confident in 1801.
Those that were predicting Sareum going into administration or the SP going to 1p on share dilution are a magnitude of order out.
There were those that wanted Sareum to collapse. Some will be disappointed with this.
Now ask yourselves a question.
Where would Sareum be if investors here sold all their shares 7 months ago?
I doubt Sareum would have been able to raise any funds at all and there would be many ie the last to leave that would own shares worth nothing.
Fortunately this did not play out.
We can now look forward to substantial increase in share value on good development news.
Nigh 20k invested by the BoD of which Parker will get 10k through WRAP.
I have put an application in but l along with others believe this will be over subscribed.
I will know next Wednesday should l not be allocated the amount l have supplied for.
I don't think l will get anywhere near 50k shares and that being very much less than supplied for.
Puma unfortunately sonny you will not be able to participate in this.
Overall the RNS's are good.
It allows us to progress 1801 without restraint.
Yippee
Onwards and upwards.